HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

E.l.f. Beauty’s Q3 Sales Jump 49% With ‘A Lot’ Of Runway Ahead, CEO Says

Executive Summary

Oakland, CA-based e.l.f. Beauty is significantly increasing its full fiscal year 2023 sales estimate, predicting 38%-39% growth after third quarter sales soared 49% to reach $146.5m. CEO Tarang Amin discusses the white space opportunities contributing to a bullish outlook even beyond the fiscal year.

You may also be interested in...



E.l.f. Facing Off Against Beauty Giants: Third Among Mass Market Brands As Sales Jump 78%

E.l.f. cosmetics climbed to No. 3 brand in US mass market cosmetics, up two slots from a year ago as it surpassed Revlon and CoverGirl. In its recent sales and earnings presentation, it announced sales in its fiscal 2023 fourth quarter jumped 78%.

Sephora Incubator Teams With TikTok; Teen Spending Survey; Cosmetics News Grab

Beauty brands in the Sephora Accelerate program will learn from #beautytok creators on storytelling and the importance of a DEI-first approach as part of a partnership announced in March. More cosmetics news in brief.

‘Lipstick Effect’ Holding In 2023 Despite Continuing Price Escalation – Catalina Marketing

Consumers continued to spend more on beauty products in January 2023 in US mass retail doors despite rising prices across face makeup, eye makeup and lipstick segments, according to market intelligence and consulting firm Catalina Marketing.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153337

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel